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ABSTRACT We previously produced a heavy-chain-only antibody (Ab) VH do-
main (VHH)-displayed phage library from two alpacas that had been immunized
with ricin toxoid and nontoxic mixtures of the enzymatic ricin toxin A subunit
(RTA) and binding ricin toxin B subunit (RTB) (D. J. Vance, J. M. Tremblay, N. J.
Mantis, and C. B. Shoemaker, J Biol Chem 288:36538 –36547, 2013, https://doi.org/
10.1074/jbc.M113.519207). Initial and subsequent screens of that library by direct
enzyme-linked immunosorbent assay (ELISA) yielded more than two dozen unique RTA-
and RTB-specific VHHs, including 10 whose structures were subsequently solved in
complex with RTA. To generate a more complete antigenic map of ricin toxin and to
define the epitopes associated with toxin-neutralizing activity, we subjected the VHH-
displayed phage library to additional “pannings” on both receptor-bound ricin and
antibody-captured ricin. We now report the full-length DNA sequences, binding affin-
ities, and neutralizing activities of 68 unique VHHs: 31 against RTA, 33 against RTB, and
4 against ricin holotoxin. Epitope positioning was achieved through cross-competition
ELISAs performed with a panel of monoclonal antibodies (MAbs) and verified, in some
instances, with hydrogen-deuterium exchange mass spectrometry. The 68 VHHs
grouped into more than 20 different competition bins. The RTA-specific VHHs with
strong toxin-neutralizing activities were confined to bins that overlapped two previ-
ously identified neutralizing hot spots, termed clusters I and II. The four RTB-specific
VHHs with potent toxin-neutralizing activity grouped within three adjacent bins situ-
ated at the RTA-RTB interface near cluster II. These results provide important insights
into epitope interrelationships on the surface of ricin and delineate regions of vulner-
ability that can be exploited for the purpose of vaccine and therapeutic development.
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Ricin is the prototype of the type II ribosome-inactivating protein (RIP) family oftoxins (1). Ricin toxin A subunit (RTA) is an RNA N-glycosidase that catalyzes the
hydrolysis of a conserved adenine residue within the sarcin/ricin loop (SRL) of 28S rRNA,
resulting in ribosome arrest and apoptosis (2–4). Ricin toxin B subunit (RTB) is a
galactose- and N-acetylgalactosamine (Gal/GalNAc)-specific lectin that promotes toxin
entry into mammalian cells, including the epithelial cells that line the respiratory tract
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(5, 6). Following endocytosis, RTB mediates the retrograde transport of ricin to the
trans-Golgi network (TGN) and endoplasmic reticulum (ER). Once within the ER, the
disulfide bond that links RTA to RTB is reduced by protein disulfide isomerase and RTA
is retrotranslocated (dislocated) into the cell cytoplasm, where it triggers programmed
cell death (7, 8). Ricin is classified as a category B biothreat agent by the Centers for
Disease Control and Prevention (CDC) because of its potential, when delivered via
aerosol, to induce severe lung inflammation and tissue damage (9, 10). Concerns over
ricin’s possible use as a biothreat agent stem from the fact that the toxin is relatively
easy to procure from its natural source, castor beans (Ricinus communis), as well as from
its extreme toxicity following inhalation or injection (11).
As part of a longstanding effort to engineer ricin antitoxins and immunotherapies,
we previously produced a library of phage-displayed, heavy-chain-only antibodies (Abs;
VHHs) from two alpacas that had been hyperimmunized with nontoxic mixtures of
recombinant RTA, RTB, and ricin toxoid; the library is referred to here as “HobJo” in
reference to the names of the two immunized alpacas, Hobbs and Johnnes (12). In our
initial study, the phage-displayed VHH library was subjected to high- and low-
stringency “panning” on purified native RTA or RTB that had been immobilized on
plastic substrates. This initial screening strategy yielded 11 unique RTA-specific VHHs
and 9 unique RTB-specific VHHs. Five (4 RTA-specific and 1 RTB-specific) VHHs among
the original 20 had strong or moderate in vitro toxin-neutralizing activity (TNA), while
the remaining 15 had weak TNA or no detectable TNA. A collection of homo- and
heterodimeric (i.e., bispecific) VHHs were engineered with these original 20 VHHs and
shown to have enhanced avidities for ricin and, in some cases, the capacity to passively
protect mice from lethal-dose ricin challenge (12–15). As discussed below, the X-ray
crystal structures of 10 different VHH-RTA complexes, including 7 VHHs from the original
screen (16–18), have been solved to date.
The original strategy of panning the VHH library onto RTA- and RTB-coated immu-
notubes presented several drawbacks. First, there was a bias for VHHs directed against
a single immunodominant region on RTA that we refer to as cluster I. Cluster I is defined
by the murine monoclonal antibody (MAb) PB10, which recognizes a linear epitope
encompassing -helix B (residues 94 to 107) of RTA (see Fig. S1 in the supplemental
material) (19–21). -Helix B is a secondary motif conserved across the RIP family (22).
Approximately half of the original RTA-specific VHHs recognized epitopes in cluster I,
based on competition enzyme-linked immunosorbent assays (ELISAs) performed with
PB10. The second shortcoming associated with the original screen was that it gave rise
to VHHs that recognized cryptic epitopes that are exposed when RTA and RTB are
adsorbed to polystyrene but that are not accessible to antibodies when ricin is in its
native conformation. Finally, by performing screening with individual subunits, rather
than with the holotoxin, we were likely missing antibodies directed against quaternary
epitopes. With the long-term goal of generating a saturating B cell epitope map of ricin
toxin using the HobJo library, which is estimated to contain 4  106 independent
clones, we reasoned that it would be necessary to derive novel panning strategies.
To generate a more complete antigenic map of ricin toxin and to better define the
epitopes associated with neutralizing activity, we have now subjected the HobJo
VHH-displayed phage library to pannings on both receptor-bound and antibody-
captured ricin holotoxins or subunits. We identified a total of 68 unique ricin-specific
VHHs (31 against RTA, 33 against RTB, and 4 against ricin holotoxin) and present their
full-length DNA sequences, binding affinities, and neutralizing activities. We used
cross-competition ELISAs with a panel of well-characterized murine monoclonal anti-
bodies (MAbs) as a strategy to localize the epitopes recognized by the new collection
of VHHs. Epitope positioning was validated with available X-ray crystal structures and,
in some instances, was followed up with hydrogen-deuterium mass spectrometry
(HX-MS). We identified more than 20 different competition bins (a bin was comprised
of all VHHs which shared the same competition profile) that cover 50% of RTA’s
surface area and an indefinite amount of RTB. Having this comprehensive collection of
well-characterized, ricin-specific VHHs provides important insights into epitope interre-
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lationships on the surface of ricin and delineates two or possibly three regions of
vulnerability that can be exploited for the purpose of vaccine and therapeutic devel-
opment.
RESULTS
In an effort to obtain a comprehensive map of toxin-neutralizing and nonneutral-
izing B cell epitopes on the surface of ricin, the HobJo VHH phage display library was
subjected to nine different screens (Table 1). Screens 1 to 4 involved panning on
immunotubes coated with RTA or RTB and yielded a total of 36 ricin-specific VHHs
(Tables 1 and 2). The 20 VHHs resulting from screens 1 and 2 were described previously
and included 11 against RTA (6 with TNA) and 9 against RTB (1 with TNA) (12). We
successfully solved the X-ray crystal structures of seven of those VHHs in complex with
RTA (16–18). Screens 3 and 4 yielded an additional 16 ricin-specific VHHs, including 7
against RTA, 1 of which was successfully crystallized (17), and 9 against RTB (Table 1).
Screens 5 and 6 were designed to circumvent two issues that we had encountered
in screens 1 to 4. First, roughly half of the 36 VHHs from screens 1 to 4 failed to bind
soluble ricin (R), even though they recognized plate-adsorbed ricin (R=), RTA (A=), or RTB
(B=). This finding is consistent with the exposure of cryptic epitopes on protein antigens
under conditions of binding to polystyrene surfaces (23, 24). Second, the majority of the
RTA-specific VHHs were directed against cluster I, which is defined functionally by
competition with MAb PB10 and is known to be immunodominant (12). To overcome
these issues, the HobJo library was panned, in screen 5, on ricin captured with
asialofetuin (R-ASF) to approximate the conformation of soluble ricin and, in screen 6,
on ricin that was captured with PB10 (R-PB10) to mask immunodominant epitopes
within cluster I. VHHs identified in screen 5 were cross-checked for binding to R-PB10,
while VHHs identified in screen 6 were cross-checked for reactivity with R-ASF. Only
VHHs that were positive in both assays were characterized further (Tables 1 and 2). This
strategy yielded a total of 56 VHHs that were reactive with both R-ASF and R-PB10. After
we eliminated siblings from the pool, a total of 13 VHHs remained: 10 against RTA, 2
against RTB, and 1 specific for ricin holotoxin.
Screen 7 was designed to identify VHHs that recognize two different linear epitopes
on RTA defined by the murine toxin-neutralizing MAbs PB10 and SyH7 (19). Two
biotin-tagged 18-mer peptides, E12 and G3, corresponding to the core epitopes of
PB10 and SyH7, respectively, were captured on immunotubes via the use of avidin and
then subjected to panning with the HobJo library. The screen proved unsuccessful,
TABLE 1 Summary of HobJo screens
Screenc Target(s)d
No. of VHHs with indicated
specificitya TNAb
A B R Total    
1 RTA 11 0 0 11 2 2 2 5
2 RTB 0 9 0 9 1 0 0 8
3 RTA 7 0 0 7 0 2 2 3
4 RTB 0 9 0 9 0 0 0 9
5 R-ASF 5 0 1 6 0 1 1 4
6 R-PB10 5 2 0 7 1 0 1 5
7 Peptides 0 0 0 0 0 0 0 0
8 RTB-ASF 0 5 0 5 0 0 1 4
9 R-F5  F6 4e 8 3 15e 3 2 0 9
Total 31 33 4 68e 7 7 7 47
aA, RTA; B, RTB; R, ricin holotoxin.
bToxin neutralizing activity, based on IC50, indicated as follows: , IC50  10 nM; , IC50  100 nM; ,
IC50  500 nM; , IC50  500 nM or undetectable.
cVHHs in screens 1 and 2 were reported previously (12).
dR-ASF, ricin captured by ASF; R-PB10, ricin captured by PB10; RTB-ASF, RTB captured by ASF; R-F5  F6,
ricin captured with VHH JIV-F5 and then blocked with excess JIV-F6.
eOne anti-RTA VHH from screen 9 was not successfully expressed and thus was not characterized for TNA
and also was not included in the final VHH total of 68.
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TABLE 2 Properties of ricin-specific VHHs described in this study
VHH Screena
GenBank
accession no. PDB IDb TNAc KD (nM)d Specificitye Cluster(s)f Familyg
JIV-F5 1 KF746018 4Z9K  0.019 A I
JIV-F6 1 KF746019  1.86 A III JIV-F6
JIV-G12 1 KF746020 4LGS  0.129 A I
JIY-A7 1 KF746021 4LHQ  4.3 A I JIY-A7
JIY-D9 1 KF746022  0.174 A I  II JIY-D9
JIY-D10 1 KF746023 4LGR  0.114 A I  II
JIY-E1 1 KF746024 5BOZ  0.686 A II
JIY-E3 1 KF746025  0.296 A I
JIY-E5 1 KF746026 4LGP  0.191 A I  IV
JIY-F10 1 KF746027  NB A’
JIY-G11 1 KF746028 4LHJ  0.553 A I
JIW-B1 2 KF746029  NB B’
JIW-C12 2 KF746030  NB B’
JIW-D12 2 KF746031  NB B’ JIZ-B7
JIW-G5 2 KF746032  NB B’
JIW-G10 2 KF746033  NB B’ JIW-G10
JIZ-B7 2 KF746034  0.031 B SII JIZ-B7
JIZ-B9 2 KF746035  NB B’
JIZ-D8 2 KF746036  NB B’
JIZ-G4 2 KF746037  NB B’
JNM-A11 3 KY824576  0.200 A I
JNM-B5 3 KY824577  0.060 A I
JNM-C12 3 KY824578  0.099 A I  IV
JNM-D1 3 KY824579  1.19 A II  III
JNM-E4 3 KY824580  0.083 A I
JNM-F8 3 KY824581 5E1H  0.203 A I
JNM-G4 3 KY824582  0.128 A I JIY-A7
JNN-A3 4 KY824583  NB B’ JIW-G10
JNN-B6 4 KY824584  NB B’
JNN-B8 4 KY824585  NB B’ JIZ-B7
JNN-C5 4 KY824586  NB B’
JNN-C8 4 KY824587  NB B’
JNN-D1 4 KY824588  NB B’ JIZ-B7
JNN-D8 4 KY824589  NB B’
JNN-E4 4 KY824590  NB B’
JNN-H9 4 KY824591  NB B’
V1B4 5 KY824592  4.09 R SII
V1B10 5 KY824593  0.917 A III JIV-F6
V1B11 5 KY824594  8.84 A I  III
V1C7 5 KY824595 5J56  3.19 A II V1C7
V1D3 5 KY824596  0.460 A III JIV-F6
V1G6 5 KY824597  5.34 A III V2G10
V2A11 6 KY824598  1.82 A III
V2B8 6 KY824599  32.4 A I  II JIY-D9
V2B9 6 KY824600  1.03 A II V1C7
V2C11 6 KY824601  0.015 B SII V2C11
V2D4 6 KY824602  3.2 B SII V2C11
V2E8 6 KY824603  5.74 A II V1C7
V2G10 6 KY824604  1.16 A III V2G10
V4A1 8 KY824605  0.667 B SII
V4C6 8 KY824606  NB B V4C6
V4C8 8 KY824607  NB B V4C6
V4D12 8 KY824608  NB B
V4G3 8 KY824609  NB B
V5A2 9 KY824610  1.46 A III
V5B1 9 KY824611  2.17 B
V5B6 9 KY824612  0.668 B
V5C1 9 KY824613  0.301 A II V1C7
V5C4 9 KY824614  5.01 B
V5D1 9 KY824615  0.216 R SII
V5D5 9 KY824616  5.54 B
V5E1 9 KY824617 5J57  0.019 A II
V5E4 9 KY824618  0.006 B SII
V5G1 9 KY824619  0.106 B SII
(Continued on next page)
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however, as none of the 100 clones that we examined bound to ricin or either of the
E12 or G3 peptides (data not shown). The failure to obtain E12- or G3-specific VHHs was
not completely surprising, considering that there are very few examples of single-
domain antibodies that recognize linear epitopes, possibly because of the absence of
a light chain to provide a cleft for peptide binding (25, 26).
Two final screens were conducted using the HobJo library. Screen 8, which was
designed to enrich for VHHs that bind native (not cryptic) epitopes on RTB, involved
panning the HobJo library on RTB captured via ASF (RTB-ASF). The screen gave rise to
five unique RTB-specific VHHs. In screen 9, the VHH library was panned using two VHHs
identified in screen 1; ricin holotoxin was captured with JIV-F5 to obstruct immuno-
dominant epitopes in cluster I and then saturated with JIV-F6 to mask a subdominant
epitope in cluster III (R-F5  F6). The screen yielded a total of 15 unique VHHs, including
4 targeting RTA (3 of which were successfully expressed), 8 targeting RTB, and 3
targeting ricin holotoxin.
In total, the nine screens resulted in 68 unique anti-ricin VHHs: 31 specific for RTA,
33 specific for RTB, and 4 specific for ricin holotoxin (Tables 1 and 2). Fourteen
additional VHHs (7 anti-RTA and 7 anti-RTB) found in various screens were dropped
from further study because of their similarity to other VHHs (i.e., with very few, generally
conservative mutations, usually within framework regions) or, in one case, because the
VHH failed to be expressed at sufficiently high levels in Escherichia coli to be amenable
to analysis (see Table S1 in the supplemental material). The complementarity deter-
mining region 3 (CDR3) nucleotide sequences of the entire collection of VHHs were
aligned using BLAST and grouped into families based on length and nucleotide
identity. There were nine different clonal families encompassing a total of 24 VHHs
(Tables 2 and 3); the remaining 44 VHHs were unrelated to each other. The VHH
sequences have been deposited in GenBank (Table 2). Within the group of 68 VHHs,




accession no. PDB IDb TNAc KD (nM)d Specificitye Cluster(s)f Familyg
V5G6 9 KY824620  1.24 R SII
V5G12 9 KY824621  0.994 R SII
V5H2 9 KY824622  2.18 B SII V2C11
V5H6 9 KY824623  23.2 B
aVHHs in screens 1 and 2 were reported previously (12).
bProtein Data Bank IDs.
cToxin-neutralizing activity (TNA), as described in the legend of Table 1.
dNB, no binding detected in SPR.
eA, RTA; A=, RTA=; B, RTB; B=, RTB=; R, ricin holotoxin.
fData represent RTA epitope cluster(s) (I to IV) bound by a particular VHH. SII refers to “supercluster II” and is the designation given to RTB- or holotoxin-specific VHHs
that are subject to competition from RTA binding cluster II MAb SyH7.
gSee Table 3 for descriptions of families.
TABLE 3 VHH families based on CDR3 similaritya
Familyb Member(s) Specificityc
JIV-F6 V1B10, V1D3 A
JIY-A7 JNM-G4 A
JIY-D9 V2B8 A
V1C7 V2B9, V2E8, V5C1 A
V2G10 V1G6 A
JIZ-B7 JIW-D12, JNN-B8, JNN-D1 B
JIW-G10 JNN-A3 B=
V2C11 V2D4, V5H2 B
aBold and underlined data indicate a VHH with strong TNA; bold data indicate moderate TNA; underlined
data indicate weak TNA.
bA family was defined as composed of two or more VHHs having CDR3 sequences of equal lengths and
90% identity at the nucleotide level.
cA, RTA; B, RTB; B=, plate-bound RTB.
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Classification and characterization of ricin-specific VHHs. All 68 VHHs were
expressed in E. coli as 33- to 35-kDa E-tagged thioredoxin fusion proteins, as described
in the supplemental methods and in previous publications (12). The relative purity and
integrity of the VHH preparations were assessed by SDS-PAGE (Fig. 1A). Each of the 68
ricin-specific VHHs was also assessed for the ability to neutralize ricin toxin in a Vero cell
cytotoxicity assay (Fig. 1B and Table 2) (27, 28). Relative 50% inhibitory concentrations
(IC50s) were determined by mixing each VHH at a range of concentrations (0.01 to
10,000 nM) with a fixed amount of ricin before applying it to Vero cells, as described in
Materials and Methods. The VHHs were assigned to one of four groups based on their
relative IC50s as follows: 10 nM, strong toxin-neutralizing activity; 100 nM, moderate
toxin-neutralizing activity; 500 nM, weak toxin-neutralizing activity; 500 nM, no
neutralizing activity. The majority (80%) had weak (n  7) or no detectable (n  47)
FIG 1 Expression and characterization of ricin-specific VHHs. All 68 VHHs in this study (Table 2) were subjected to analysis by
SDS-PAGE, toxin-neutralizing assays, and competition ELISA. Data shown here represent results of analysis of five represen-
tative RTB-specific VHHs: V5B6, V5D5, V5E4, V5G1, and V5H6. (A) VHHs were subjected to SDS-PAGE, and the resulting gel was
stained with Coomassie blue. Molecular mass standards (with kilodalton notations) are shown in the far left lane. The major
band (33 to 35 kDa) in each lane corresponds to the expected molecular mass of the recombinant VHHs, with an N-terminal
thioredoxin fusion partner, a hexa-His tag, and a C-terminal epitope E-tag, as described in the supplemental methods. (B)
Toxin-neutralizing activity, as determined in a Vero cell-based microtiter plate assay. The representative set of VHHs consists
of two VHHs with strong TNA (IC50  10 nM) and three with no TNA. (C) Competition ELISA, as described in Materials and
Methods. Microtiter plates were coated with the indicated MAbs or ASF (legend on right) and then overlaid with ricin. The
plates were probed with VHHs, as indicated along the x axis, and were developed with anti-E-tag secondary antibodies. As such,
the sandwich ELISA data provided relative competition values against a panel of RTA- and RTB-specific MAbs. The failure of
the VHHs to recognize ricin toxin when bound to ASF is indicative of the antibodies recognizing epitopes near one of the RTB
Gal/GalNAc binding sites. The full array of competition ELISAs is presented in Data Set S1.
Vance et al. Clinical and Vaccine Immunology
December 2017 Volume 24 Issue 12 e00236-17 cvi.asm.org 6
 on N
ovem







TNA, while the remainder (20%) were evenly divided between strong (n  7) and
moderate (n  7) toxin-neutralizing activities (Tables 1 and 2). The results of the
toxin-neutralizing assays performed for the 14 VHHs with strong or moderate TNA are
shown in Fig. S2 in the supplemental material. Among the seven VHHs with the
strongest TNA, three were specific for RTA and four were specific for RTB.
VHH association (Ka) and dissociation (Kd) rates and equilibrium dissociation con-
stants (KD) for ricin were determined by surface plasmon resonance (SPR) using sensor
chips coated with native toxin via amine coupling, as described in Materials and
Methods. Kinetic constants were fitted using the Langmuir 1:1 binding model (29). We
found that KD values ranged from 6 pM to 32 nM (Table 2; see also Table S2 and Fig.
S3 in the supplemental material). In general, the VHHs with the highest binding affinity
(KD) generally had the strongest TNA (R2  0.6966; Fig. 2A). For example, all 14 VHHs
with strong and moderate TNA had KD values of 1 nM, while VHHs with KD values of
1 nM lacked TNA, with one exception. Furthermore, the VHHs with the strongest TNA
also tended to have the slowest off-rates (Kd) (R2  0.6018; Fig. 2B), a relationship that
has been noted by other investigators (30). The relationship between binding affinity
and TNA was most apparent within VHH clonal families (Fig. 2C), the members of which
would be expected to have epitopes similar to each other (31). The failure of antibodies
such as JNM-B5 to neutralize ricin despite its relatively high binding affinity (e.g., 60 pM)
demonstrates once again that other factors such as epitope specificity contribute to
antibody functionality.
Localization of VHH epitopes on RTA. We next sought to locate the relative
binding sites of all VHHs that recognized soluble ricin, with the expectation that
toxin-neutralizing antibodies would segregate into specific bins or clusters of epitopes
on RTA and RTB.
We addressed RTA first. In collaboration with Michael Rudolph (New York Structural
Biology Center, New York, NY), all 30 RTA-specific VHHs (excepting JIY-F10, which did
not recognize soluble ricin) have been subjected to X-ray crystallography trials. To date,
we have reported 10 VHH-RTA cocrystal structures: 6 that involve epitope cluster I, 3
that involve epitope cluster II, and 1 that straddles clusters I and II (Table 2) (16–18). The
two cluster I VHHs with the strongest TNA, JIY-E5 and JIV-F5, each make considerable
contact with RTA’s -helix B (i.e., 472 to 477 Å2), an interaction that has been
proposed to be critical for toxin inactivation (17–22, 26, 32). The other cluster I VHHs,
and the cluster I/II VHH, interacted with -strand h and -helix D to various degrees.
Within cluster II, the two VHHs with weak TNA, V1C7 and JIY-E1, made primary contact
with -helices D and E, while V5E1, which has strong TNA, associated with -helices A
and F and the F-G loop. For perspective, we provide a PyMol surface representation of
all 10 solved VHH structures superimposed onto RTA (see Fig. S4 in the supplemental
material).
In the absence of additional X-ray crystal structures, epitope localization on RTA was
done by competitive sandwich ELISA with a collection of nine different MAbs against
epitopes in clusters I (PB10 and WECB2), I and II (SWB1), II (SyH7, PA1, TB12, and PH12),
III (IB2), and IV (GD12) (Fig. 3; see also Table S3 in the supplemental material) (19, 20,
53). As described in Materials and Methods, each of the 30 anti-RTA VHHs was tested for
the ability to recognize ricin that had been captured by each of the nine cluster I to IV
MAbs. The validity of the sandwich ELISA for epitope mapping was evaluated using the
following three VHHs whose epitopes have been resolved by X-ray crystallography (Fig.
4): JIV-F5 (PDB identifier [ID]: 4Z9K), JIY-D10 (PDB ID: 4LGR), and V1C7 (PDB ID: 5J56)
(16–18). In the sandwich ELISA, the binding of JIV-F5 to ricin was affected by PB10,
WECB2, and SWB1 but not by SyH7, PA1, PH12, TB12, IB2, or GD12 (Fig. 4A). This
competition profile is consistent with the structural epitope of JIV-F5 encompassing
-helix B, -strand h, and the C-terminal portion of -helix D (17). By the same token,
JIY-D10 was able to bind to ricin that had been captured by GD12, PB10, PA1, SyH7, and
IB2 but not WECB2, SWB1, TB12, or PH12, a profile congruent with JIY-D10’s structural
epitope being localized to -helices D and E and -strand h (Fig. 4B). Finally, V1C7 was
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able to bind ricin that had been captured by GD12, PB10, WECB2, and IB2 but not the
cluster II-specific MAbs (SyH7, PA1, PH12, and TB12) or the I-II overlap MAb SWB1. This
profile is consistent with V1C7 making contact with RTA’s -helix D and -helix E, along
with several additional interactions with loops e-d, C-D, and D-E (16) (Fig. 4C). The
sandwich ELISA also successfully positioned the epitopes of the seven additional VHHs
(JIV-G12, JIY-A7, JIY-E1, JIY-E5, JIY-G11, JNM-F8, and V5E1) whose X-ray crystal structures
in complex with RTA have been solved (16–18) (see Data Set S1 in the supplemental
material). However, it is important to note that the epitope localization determined by
the sandwich ELISA is only approximate, as the assay does not discriminate between
direct epitope overlap, steric hindrance, and allostery. Indeed, we noted that the
sandwich ELISA overestimated V1C7’s contact on RTA compared to its known structural
epitope as defined by X-ray crystallography (see Fig. S5).
FIG 2 Relationships between VHH binding affinities and toxin-neutralizing activities. (A and B) Using
values presented in Table 2, toxin-neutralizing activity (percent viability at 66 nM VHH) of representative
VHHs was plotted versus its respective (A) equilibrium dissociation constant (KD) or (B) off-rate (Kd) value.
For simplicity’s sake, individual VHHs are color coded based on their neutralizing activity (i.e., strong,
moderate, weak, or no neutralizing [Non] activity). To enable the use of a logarithmic axis, VHHs that
lacked TNA were arbitrarily assigned a value of 1 for percent viability (x axis). R2 values were calculated
using the Power Trendline function in Microsoft Excel. (C) TNA as a function of equilibrium dissociation
constant (KD) for the six VHH clonal families represented in Table 3. Each color represents a family; each
dot represents an individual VHH within that family. The downward slope of the lines suggests a
relationship between KD and TNA within a clonal family (i.e., VHHs with the highest affinity for ricin also
have the strongest TNA). The percentages of cell viability as plotted are from a single representative
experiment done in triplicate.
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The sandwich ELISA was next used to approximate the binding sites of the remain-
ing 20 RTA-specific VHHs on the surface of RTA relative to clusters I to IV. All 20 VHHs
were inhibited from binding to ricin by at least one MAb, and the majority (16/20) were
inhibited by two or more MAbs (Fig. 5; see also Fig. S6 and Data Set S1 in the
supplemental material). In total, the 30 anti-RTA VHHs fell into 11 different competition
profiles, or “bins” (a bin was comprised of all VHHs which shared the same competition
profile). When the bins were aligned vertically and the epitope clusters horizontally, as
shown in Fig. 5, it was evident that the putative VHH binding sites were spatially
contiguous across the four previously identified epitope clusters. Moreover, each of the
11 competition bins overlapped WECB2 (cluster I; bins 1 to 6), SyH7 (cluster II; bins 7
and 8), or IB2 (cluster III; bins 9 to 11), suggesting that these three MAbs constitute the
immunodominant regions on RTA.
Overall, the competition profiles associated with each of the bins enabled us to
assign their location on the surface of RTA with confidence, especially if a bin contained
one or more VHHs whose X-ray crystal structure in complex with RTA has been solved.
Bin 2, for example, is defined by competition with PB10, WECB2, and SWB1. These three
MAbs have overlapping epitopes on RTA’s -helix B, -strand h, and -helix D and the
D-E loop (53). Moreover, the structural epitopes of five of the nine VHHs in bin 2 have
been reported (17, 18). Therefore, we can assume that the remaining four VHHs in bin
2, JIY-E3, JNM-B5, JNM-E4, and JNM-G4, contact -helix B, -strand h, and/or -helix D
(Fig. 3; see also Fig. S1).
Similarly, bin 7 is defined by competition with SWB1 and all four cluster II MAbs
(PH12, TB12, PA1, and SyH7). PA1 and SyH7 contact the loop before -helix A and
-helices F and G, while PH12, TB12, and SWB1 contact -strand d and -helices D and
E. Moreover, as noted above, the structural epitopes of two VHHs in bin 7, JIY-E1 and V1C7,
FIG 3 Representative landmarks and functional elements on ricin toxin. Surface (top) and ribbon
(bottom) PyMol representations of ricin toxin (PDB ID: 2AAI) at 120° rotations. Landmarks on RTA (gray)
include the epitopes recognized by WECB2 (blue), SWB1 (magenta), SyH7 (orange), IB2 (green), and the
active site (yellow). Landmarks on RTB (black) include the two galactose binding sites (lactose moieties
in red) and subdomains 2 (pink) and 2 (cyan).
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have recently been reported (16). The remaining three VHHs in bin 7, V2B9, V2E8, and
V5C1, are members of the V1C7 family (Table 3). Rosetta-based homology modeling
suggests that the V1C7 family members, despite their minor differences in CDR
sequences, interact with RTA in similar fashions (31). Thus, the epitopes of all five VHHs
in bin 7 can be positioned on RTA with relative accuracy.
In some instances, the results of the sandwich ELISA were more difficult to reconcile.
In the case of V1B11 and JNM-D1, representing bins 6 and 10, respectively, considerable
cross-cluster competition was involved. V1B11 was competed with by WECB2 (cluster
I) and IB2 (cluster III), while JNM-D1 was affected by SyH7 (cluster II) and IB2 (cluster III).
When the cross-cluster competition results were taken at face value, the predicted
epitopes for V1B11 and JNM-D1 encompassed too large a surface on RTA to localize
actual antibody-antigen contact points (Fig. 6). To refine these ambiguous antibody
binding sites, we subjected V1B11 and JNM-D1 to epitope mapping by hydrogen-
deuterium exchange mass spectrometry (HX-MS), as described recently (31). HX-MS
affords peptide-level resolution of antibody binding sites and is therefore an extremely
useful methodology for epitope localization (33). As part of this analysis, we also
included JNM-C12 (bin 1) since it also demonstrated a degree of cross-cluster compe-
tition.
JNM-C12’s binding to ricin was inhibited by cluster I (PB10 and WECB2), cluster I/II
(SWB1), and cluster IV (GD12) MAbs (Fig. 6A). This profile differs from that seen with bin
2, for which we have several crystal structures, determined solely by competition with
cluster IV (GD12). On the basis of this profile, we predicted that JNM-C12’s core epitope
would encompass RTA’s -helix B and -strand h and might also potentially include
-strands b to d. This prediction was partially borne out when JNM-C12 was subjected
to epitope mapping by HX-MS. Specifically, JNM-C12 strongly protected RTA peptides
corresponding to -helix B (residues 92 to 109) and -strand h (residues 108 to 122) but
did not protect -strands b to d (see Fig. S7A and Table S5 in the supplemental
FIG 4 Validation of cross-competition ELISA as a strategy for epitope localization on RTA. (Top panels) VHHs (A) JIV-F5, (B) JIY-D10, and (C) V1C7
were subjected to competition ELISAs with a panel of RTA-specific MAbs representing neutralizing clusters I to IV, as described in Materials and
Methods. As a point of reference, VHH binding to R-ASF is shown in each panel (gray). (Bottom panels) The known X-ray crystal structures of VHHs
(colored red) (A) JIV-F5, (B) JIY-D10, and (C) V1C7 bound to RTA with relevant murine MAb epitopes (clusters I to IV), color coded as in the top
panel. PDB IDs are 4Z9K (JIV-F5), 4LGR (JIY-D10), and 5J56 (V1C7).
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material). Thus, competition with GD12 may be steric in nature. In this respect,
JNM-C12’s core epitope involves contact with -helix B and -strand h and resembles
VHHs in bin 2.
The sandwich ELISA predicted that JNM-D1 would recognize -helices C and G and
the F-G loop (Fig. 6B). Again, HX-MS analysis partially confirmed this prediction, as
JNM-D1 strongly protected peptides encompassing RTA’s -helices C (residues 123 to
135) and G (residues 205 to 210) but not the F-G loop (see Fig. S7B and Table S5 in the
supplemental material). On the basis of the sandwich ELISA, V1B11 was predicted to
recognize an epitope situated between -strand h and -helix C (Fig. 6C). HX-MS
analysis of V1B11 revealed that it strongly protected RTA’s -helices C (residues 123 to
135) and G (residues 205 to 210), consistent with the observed IB2 results (see Fig. S7C
and Table S5). Thus, HX-MS enabled us to predict with greater confidence the epitopes
of V1B11 and JNM-D1 on RTA. Interestingly, despite the differential competition profiles
of these two VHHs, their binding epitopes as determined by HX-MS are almost identical.
Thus, the sandwich ELISA may provide additional information regarding the orientation
of binding of these VHHs to that footprint on RTA, which results in differential steric
hindrance with WECB2 and SyH7.
HX-MS also revealed another interesting difference between JNM-D1 and V1B11 in
residues 249 to 255, which span a 3/10-helix and a -bridge in RTA’s C terminus. This
region is on the opposite side of RTA from the residues in helices C and G that are
FIG 5 Relative locations of the epitopes recognized by 30 different RTA-specific VHHs. Thirty RTA-specific VHHs (left
column) were subjected to cross-competition sandwich ELISA with a panel of nine murine MAbs (top row)
representing the four different epitope clusters on RTA. Shown here is a binary representation of the actual
sandwich ELISA (Fig. S6) in which individual cells are colored red for 50% competition (VHH versus MAb) and
green for 50% competition. VHH clonal families are boxed (left column). VHHs with the same competition profile
were grouped into bins (right column). For reference, VHH binding affinities and TNA (from Table 2) are shown in
the far right columns.
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strongly protected by both VHHs and would not be exposed to solvent in the context
of ricin holotoxin. While JNM-D1 induced strong deprotection (i.e., increased flexibility
leading to faster hydrogen exchange) in this region, V1B11 induced strong protection
(see Fig. S7B and C in the supplemental material). We hesitate to speculate about the
significance of the observed deprotection/protection associated with RTA’s C terminus,
considering that this region of RTA is prone to unfolding in the absence of RTB.
Nonetheless, the observation that two VHHs (JNM-D1 and V1B11) with seemingly
identical binding sites (and similar affinities) have opposite effects (protection versus
deprotection) on RTA’s C terminus raises interesting questions about potential allosteric
changes that can occur within the context of ricin toxin.
Spatial location and secondary elements on RTA associated with neutralizing
epitopes. We had originally proposed that toxin-neutralizing antibodies would be
confined to a very limited number of sites on RTA, a hypothesis that proved to be
somewhat accurate. As shown in Fig. 5, although VHHs with strong and moderate TNA
were distributed across six different bins (namely, bins 1, 2, 5, 7, 8, and 9), the six bins
likely constitute two hot spots. One hot spot, defined by competition with WECB2 and
SWB1 and represented by JNM-C12, JIV-F5, and JIY-D10, among others, involves -helix
B and possibly the C-terminal portion of -helix D (Fig. 3; see also Fig. S1) (17, 18).
FIG 6 Confirmation of epitope positioning by HX-MS. (Left column) VHHs (A) JNM-C12, (B) JNM-D1, and (C) V1B11 were
subjected to cross-competition ELISAs, as described in the legend to Fig. 4. (Middle column) Based on the competition profiles,
the predicted epitopes recognized by JNM-C12, JNM-D1, and V1B11 were positioned on the surface of RTA (PDB ID: 1RTC).
(Right column) Results of HX-MS analysis of JNM-C12, JNM-D1, and V1B11 (Fig. S7), mapped onto RTA. The regions of strong
protection, shown in the same orientation as in the middle column for comparison, are indicated using cluster-specific colors.
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Although -strand h sits between these structural elements, evidence provided by
X-ray crystal structure analysis suggests that the interaction with strand h alone is not
sufficient to confer TNA (17, 18). The other hot spot, defined by competition with SyH7
and PA1 and represented by V5E1, involves contact with the loop preceding -helix A,
-helix F itself, and the F-G loop, with the F-G loop likely the critical determinant of
strong neutralizing activity (16).
With that in mind, we can account, at the structural level, for strong and moderate
TNA associated with other RTA-specific VHHs. VHHs in bins 1 to 6 with detectable TNA
(e.g., JNM-E4) would be predicted to engage with -helix B and/or -helix D, while VHHs
in bins 7 and 8 would be expected to contact -helix F and the F-G loop. V5C1 (bin 7)
sits between these two hot spots, being competed with by all three of SWB1 and
SyH7/PA1, and thus may neutralize via contact with either or both hot spots. V1D3 (bin
9) is interesting because it is competitively inhibited by both IB2 and SWB1. On the
basis of this profile, V1D3 would be expected to make contact with -helices C and G
and/or the C-terminal portion of -helix D. Its neutralizing activity may therefore be due
to contact with -helix D and/or proximity to the F-G loop. Alternatively, it may
represent a third neutralizing hot spot associated with -helix C.
The story is more complicated, however, because even among VHHs with identical
competition profiles there were often disparities in TNA that are explained only partially
by binding affinities (KD). In bin 2, for example, JIV-F5, JNM-B5, and JNM-G4 have
identical competition profiles and similar binding affinities (0.02 nM, 0.06 nM, and 0.128
nM, respectively) but very different neutralizing activities; JNM-B5 lacks TNA, JNM-G4
has weak TNA, and JIV-F5 has strong TNA. On the basis of the six reported structural
epitopes in this area of RTA (17, 18), we hypothesize that JNM-B5 engages solely with
-strand h and not with -helix D or -helix B. CDR3 of JIV-F5 is relatively short (16
residues) and contains a disulfide bond between Cys50 and Cys97 that renders it
spatially constrained; we previously showed that its short length and constrained
conformation prevent the formation of an intermolecular -sheet with -strand h (17).
In contrast, JNM-B5 and JNM-G4 have longer CDR3 sequences (19 and 22 residues,
respectively) that are devoid of the cysteine residues necessary for disulfide bond
formation. In this respect, JNM-B5 and JNM-G4 resemble JIY-G11 (PDB ID: 4LHJ), JIY-A7
(PDB ID: 4LHQ), and JIV-G12 (PDB ID: 4LGS), whose unconstrained CDR3 elements form
strand-strand interactions with -strand h. However, definitive conclusions about the
actual contact points for JNM-B5 and JNM-G4 on RTA await HX-MS and/or X-ray crystal
structure analysis.
Epitope localization of toxin-neutralizing and nonneutralizing RTB- and ricin
holotoxin-specific VHHs. We next turned our attention to the 20 VHHs isolated from
the HobJo library that were RTB or holotoxin specific and that could bind to soluble
ricin. Using a sandwich ELISA with five benchmark anti-RTB MAbs (see Table S4 in the
supplemental material), four RTA-specific cluster II MAbs (SyH7, PA12, PH12, and TB12),
and the surrogate receptor, ASF, we tentatively localized the epitopes recognized by 16
of the RTB- and holotoxin-specific VHHs (Fig. 1C and 7; see also Fig. S8 and Data Set S1).
Four VHHs were unaffected by the panel of MAbs used in the sandwich ELISA, indicating
that they recognize epitopes situated outside our existing panel of MAbs.
The 16 RTB- and holotoxin-specific VHHs constituted 12 different bins, based on their
competition profiles in the sandwich ELISA. The 11 VHHs in bins 1 to 7 shared the
common trait, in the sandwich ELISA, of being inhibited by PA1 and SyH7, a finding that
has important implications for epitope localization on RTB. SyH7 and PA1 each make
contact with RTA near the interface with RTB’s subdomains 2 (residues 148 to 183) and
2 (residues 228 to 262) (Fig. 3) (53). We would predict, therefore, that all 11 VHHs in
bins 1 to 7 recognize epitopes within RTB’s subdomains 2 and/or 2 and that the
observed competition with SyH7 and PA1 in the sandwich ELISA is due to steric
hindrance. VHHs in bins 1 to 3 would be predicted to bind epitopes abutting the
RTA-RTB interface, based on the observed competition with TB12 and PH12, whose
epitopes are considerably “north” of the border. In fact, V5D1, V5G12, and V1B4
(comprising all of bins 1 and 2) bind ricin holotoxin, but not the individual subunits,
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indicating that they recognize quaternary epitopes that straddle the RTA-RTB interface.
Finally, based on the observed competition with ASF, VHHs in bins 5 and 6 are predicted
to have epitopes situated in close proximity to (or even overlapping) the Gal/GalNAc
recognition element in subdomain 2 (Fig. 3). Elsewhere, we report results of extensive
cross-competition studies performed to refine the epitopes on RTB’s domain 2 recog-
nized by the 11 VHHs in bins 1 to 7 (A. Y. Poon, D. Vance, Y. Rong, D. Ehrbar, and N.
Mantis, unpublished data).
Bins 8 to 12 each contained a single VHH. On the basis of competition with SylH3
and JB4, we would propose that V5H6 (bin 8) and V5D5 (bin 10) also recognize epitopes
in RTB domain 2. Moreover, the fact that V5D5 is unable to recognize R-ASF suggests
that its epitope is occluded upon RTB-receptor interaction and is therefore in close
proximity to the Gal/GalNAc recognition domain but on the opposite side from VHHs
in bins 5 and 6. In contrast, V5C4 (bin 11) and V5B1 (bin 12) were each competitively
inhibited from binding to ricin by 24B11, which is postulated to recognize RTB
subdomain 1 (34–36). V5B1 was also unable to recognize R-ASF, presumably because its
epitope is near the domain 1 Gal-specific binding element (5). We recently identified
three additional MAbs specific for RTB’s domain 1, although they were not included in
this study (37).
Among the 20 RTB- and holotoxin-specific VHHs isolated from the HobJo library, four
were classified as having strong TNA, one moderate TNA, and three weak TNA (Fig. 7
and Table 2). The four VHHs with strong TNA had KD values of 110 pM and were
located in bins 3 (JIZ-B7), 4 (V5E4 and V5G1), and 5 (V2C11). They are also defined by
competition with the two anti-RTA MAbs, SyH7 and PA1. On the basis of their
competition profiles, we hypothesize that JIZ-B7, V5E4, V5G1, and V2C11 recognize a
neutralizing hot spot at the RTA-RTB interface. Two V2C11 family members, V2D4 and
V5H2, are also predicted to target this hot spot but have only weak TNA, probably
because of their relatively low binding affinities.
Along those same lines, it should be underscored that V5E1 and JIZ-B7 have
identical competition profiles, even though V5E1 is classified as an RTA-specific anti-
body and JIZ-B7 as an RTB-specific antibody (Fig. 5 and 7). Had we conducted the
epitope binning studies with ricin holotoxin rather than the individual RTA and RTB
FIG 7 Relative locations of the epitopes recognized by holotoxin- or RTB-specific VHHs. Twenty holotoxin
(*)- or RTB-specific VHHs (left column) were subjected to cross-competition sandwich ELISA with a panel of
nine murine MAbs and ASF (top row). Shown here is a binary representation of the actual sandwich ELISA
(Fig. S8) in which individual cells are colored red for 50% competition (VHH versus MAb) and green for
50% competition. VHHs with the same competition profile were grouped together into bins (right
column). For reference, VHH binding affinity data and TNA data (from Table 2) are shown in the far right
columns.
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subunits, V5E1 and JIZ-B7 would theoretically have been in the same bin. We speculate
that JIZ-B7 recognizes a quaternary epitope that straddles the RTA-RTB border, possibly
even in a configuration that mirrors V5E1 (16).
DISCUSSION
In this study, we sought to advance our longstanding efforts to generate a com-
prehensive B cell epitope map of ricin toxin with a focus on localizing the epitopes
recognized by toxin-neutralizing antibodies. Ricin’s enzymatic subunit (RTA) is of
particular interest to the biodefense research community as two recombinant RTA-
based vaccines, RiVax and RVEc, are being evaluated in preclinical and clinical studies
(38–40). Predicting the efficacy of these two vaccine candidates in humans is challeng-
ing, because neither the anti-ricin serum IgG titer nor the TNA is necessarily a reliable
predictor of protective immunity (41). However, there is evidence that epitope-specific
antibody responses may be more useful measures in this regard (42). The availability of
a high-resolution epitope map of RTA would enable a targeted analysis of specific
antibody responses following vaccination, possibly even resulting in the identification
of a serum antibody profile that correlates with immunity. Understanding the antibody
response to RTA is also relevant to the development of RTA-based immunotoxins,
whose efficacy (in some instances) has been limited by the onset of one or more
toxin-neutralizing antibodies that render the immunotoxin inactive (43, 44).
We estimate that the current collection of 68 VHHs described in this study covers
slightly more than 50% of the surface area of RTA, with a particular bias toward two
immunodominant regions of RTA, referred to as epitope clusters I and II (20). Areas not
covered in the current VHH repertoire include the entire “backside” of RTA (Fig. 3, right
panel; see also Fig. S1 in the supplemental material). In terms of RTB, we identified an
aggregate of neutralizing epitopes localized at the RTA-RTB interface positioned in
close proximity to the Gal/GalNAc recognition element of RTB’s domain 2 (5). In a
separate report, we refer to this region of RTB as “supercluster II” and demonstrate that
toxin-neutralizing activity is associated with antibody binding in the vicinity of the
RTA-RTB interface (as manifested through competition ELISA performed with SyH7 and
V5E1) rather than with obstruction of the Gal/GalNAc recognition element (A. Y. Poon,
D. Vance, Y. Rong, D. Ehrbar, and N. Mantis, unpublished data). This interfacial region
of ricin toxin is also apparently the target of a number of holotoxin-specific VHHs (e.g.,
V5D1) whose epitopes likely involve residues on both sides of the border. Unfortu-
nately, our current report does not address the mechanism(s) by which the supercluster
II antibodies neutralize ricin. We can only speculate that they interfere with a region of
the toxin that is required for retrograde transport from the plasma membrane to the ER
and/or retrotranslocation from the ER to the cytoplasm (45–48).
Nonetheless, our results are consistent with there being two putative neutralizing
hot spots on RTA, with “hot spot” being defined as a cluster of closely spaced epitopes
recognized by antibodies with potent toxin-neutralizing activity. The first hot spot
encompasses RTA’s -helix B and -helix D. The importance of -helix B as a target of
neutralizing antibodies has been recognized for more than 2 decades (22, 49), although
it is only recently that the critical holdfasts have been identified (16, 18, 21, 26, 32). The
second hot spot (as noted above) is located at the RTA-RTB interface, defined by RTA’s
-helix F and the F-G loop and (possibly) RTB’s subdomains 2 and/or 2 (16). At
present, it is not clear why these regions render ricin vulnerable to antibody attack,
although evidence is mounting that neutralization occurs intracellularly rather than
extracellularly (13, 45–47).
The HobJo VHHs described here should be a valuable resource for the ricin toxin
research community and may have important applications not only for vaccine devel-
opment but also for diagnostics and therapeutics. For example, Turner et al. recently
showed that pairing a llama-derived anti-ricin VHH (D12fneg) with a modified version
of alpaca-derived VHH JIV-F6 (F6m) yielded a highly sensitive assay that could detect
less than 1 ng/ml of ricin (12, 50). Here we have described two new JIV-F6 family
members, V1B10 and V1D3, each with higher affinities for ricin than JIV-F6. In another
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application, Legler et al. used JIV-F6, JIY-D10, and JIY-E1, along with several of their own
anti-ricin VHHs, to show that the ability of a VHH to increase the melting temperature
of RTA correlated with its neutralization ability (26). The availability of dozens of
additional VHH coding sequences, affinities, and TNAs (Table 2) enables those types
of analyses to be extended. Finally, the VHHs are amenable to recombinant engi-
neering and may provide a platform for therapeutic development. We demon-
strated, for example, that select VHH heterodimers effectively aggregate ricin in
solution and inactive the toxin in vitro and in vivo (12–14). With the available
epitope maps derived from the current study, it is now possible to rationally design
different VHH bispecific antibodies with appropriate linkers intended to target
notable hot spots on RTA and RTB.
MATERIALS AND METHODS
Ricin-specific VHH phage display library. The single-domain-antibody (VHH) library has been
described previously (12). The library is referred to as “HobJo” here in reference to the names of the two
immunized alpacas, Hobbs and Johnnes. The VHH-pIII phagemid library was maintained in E. coli TG1 at
80°C. The library was subjected to nine different screens, as described in Table 1 and in Results. Each
screen consisted of low-stringency (round 1) and high-stringency (round 2) panning procedures in which
target antigen was present at 10 g/ml and 1 g/ml, respectively. To begin each screen, an aliquot of
the library was used to inoculate Super Broth (SB) medium supplemented with 100 g/ml ampicillin and
2% glucose. The culture was grown at 37°C to an absorbance at 600 nm (OD600) of 0.6 to 0.8 and then
infected with VCSM13 helper phage carrying kanamycin resistance (Agilent Technologies, Santa Clara,
CA). After a 2-h infection at 37°C, the bacteria were pelleted at 8,000 rpm, reconstituted in SB medium
supplemented with ampicillin (100 g/ml), kanamycin (70 g/ml), and 0.1% glucose, and incubated
overnight at 30°C. The next morning, the bacteria were pelleted by centrifugation and discarded. The
resulting supernatants containing VHH-displaying phages were precipitated with 1:5 (vol/vol) 20%
polyethylene glycol (PEG 8000)–2.5 M NaCl at 4°C for 2 h. The supernatant was subjected to centrifu-
gation at 8,000 rpm for 20 min to pellet the phages, which were then resuspended in phosphate-
buffered saline (PBS) and used for round 1 of panning. Further phage panning protocols are presented
in detail in the supplemental material. Chosen VHHs were expressed as fusion proteins with an N-terminal
thioredoxin tag, a linker containing a hexa-His purification tag, and a C-terminal epitopic E-tag (GAPVP
YPDPLEPR) in E. coli Rosetta-gami 2(DE3)pLacI (EMD Millipore, Billerica, MA) as previously described (14,
15) and presented in detail in the supplemental material.
Peptides. Biotin-tagged peptides E12 (HPDNQEDAEAITHLFTDV) and G3 (IEGEMRTRIRYNRRSAPD)
used in screen 7 were synthesized by Genemed Synthesis, Inc. (San Antonio, TX).
ELISA. For cross-competition sandwich ELISAs, Nunc microtiter plates were coated with competitor
capture MAbs (1 g/ml in PBS) or ASF (4 g/ml in PBS) overnight at 4°C and then blocked for 2 h with
2% goat serum– 0.1% Tween 20 phosphate-buffered saline (PBST). Ricin (1 g/ml), RTA (0.5 g/ml), or
RTB (0.5 g/ml) was then captured by the MAbs or ASF and probed with VHH analytes at 330 nM. Bound
VHHs were detected with an anti-E tag– horseradish peroxidase (HRP) secondary antibody (Bethyl Labs,
Montgomery, TX) and developed with SureBlue TMB (3,3=,5,5=-tetramethylbenzidine) substrate (KPL).
After quenching was performed with 1 M phosphoric acid, absorbance was read at 450 nm on a
VersaMax microplate reader (Molecular Devices, Sunnyvale, CA).
Vero cell cytotoxicity assays. Relative IC50s were determined in Vero cell cytotoxicity assays, as
previously described (28). Vero cells were detached from culture dishes with trypsin, adjusted to 5
104 cells per ml, seeded (100 l/well) into white 96-well plates (Corning Life Sciences, Corning, NY), and
allowed to adhere overnight. The cells were then treated with ricin (0.01 g/ml; 154 pM), ricin-VHH
mixtures, or medium alone (negative control) for 2 h at 37°C. The cells were washed and then incubated
for 48 h at 37°C, after which cell viability was assessed using CellTiter-GLO (Promega, Madison, WI). All
treatments were performed in triplicate. Relative IC50s were determined following published guidelines
in which 100% viability was derived from cells treated with medium only, while 0% viability was defined
as the average value obtained from ricin-treated cells (51). Reported relative IC50s for each VHH were
derived from at least three independent toxin-neutralizing assays (each done in triplicate).
SPR and affinity determinations. VHH association and dissociation rates for ricin toxin were determined
by surface plasmon resonance (SPR) using a ProteOn XPR36 system (Bio-Rad Inc., Hercules, CA), as described
previously (18, 37). For ricin immobilization, general layer compact (GLC) chips were equilibrated in running
buffer (PBS–0.005% Tween) at a flow rate of 30 l/min. Following EDAC [N-ethyl-N=-(3-dimethylaminopropyl)
carbodiimide hydrochloride] (200 mM)–sulfo-NHS (N-hydroxysulfosuccinimide) (50 mM) activation (3 min),
ricin was diluted in 10 mM sodium acetate (pH 5.0) at either 4 g/ml or 2 g/ml and coupled for 2 min. A
third vertical channel received only acetate buffer and served as a reference channel. The surfaces were
deactivated using 1 M ethanolamine for 5 min. A ProteOn array system multichannel module (MCM) was
rotated to the horizontal orientation for affinity determination experiments. Each VHH was serially diluted in
running buffer and then injected at 50 l/min for 180 s, followed by 1 to 3 h of dissociation. After each
experiment, the chip was regenerated with 10 mM glycine (pH 1.5) at 100 l/min for 18 s, until the response
unit (RU) values had returned to baseline. All kinetic experiments were performed at 25°C. Kinetic constants
for the antibody/ricin interactions were obtained with ProteOn Manager software 3.1.0 (Bio-Rad Inc.) using the
Langmuir fit model.
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Epitope mapping by hydrogen deuterium exchange-mass spectrometry (HX-MS). The HX-MS
method for epitope mapping VHH antibodies is described in more detail elsewhere (R. Toth IV and D. D.
Weis, unpublished results) (31). For safety reasons, epitope mapping studies were conducted with a
nontoxic variant of RTA known as RiVax (52). Briefly, regions of RiVax where the rate of HX was
significantly lower (protection) or higher (deprotection) in the presence of bound VHH were identified
using k-means clustering and significance testing based on time-averaged HX measurements (ΔHX).
However, unlike that previous work, here the results were not filtered for the solvent accessibility of the
RiVax residues. Using k-means clustering, the regions that were assigned as showing strong and
intermediate protection were used to define the epitope. The RiVax peptides are numbered sequentially
from the N terminus to the C terminus and described in Table S5 in the supplemental material.
Molecular graphics. Images of ricin holotoxin (PBD ID: 2AAI), RTA (PDB ID: 1RTC), and RTA-VHH
complexes (see Table 2 for PDB IDs) were generated using PyMOL (The PyMOL Molecular Graphics
System; Schrodinger LLC, San Diego, CA).
Accession number(s). All VHH nucleotide sequences were deposited into GenBank (see Table 2) and
the Immune Epitope Database (IEDB) (pending).
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